• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

The development of the novel treatment that targeted plural cancer specific genes

Research Project

Project/Area Number 20591624
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Digestive surgery
Research InstitutionNagoya University

Principal Investigator

KOKURYO Toshio  Nagoya University, 医学系研究科, 特任助教 (60378023)

Co-Investigator(Kenkyū-buntansha) NGINO Masato  名古屋大学, 大学院・医学系研究科, 教授 (20237564)
YOKOYAMA Yukihiro  名古屋大学, 大学院・医学系研究科, 寄附講座講師 (80378091)
UEHARA Keisuke  名古屋大学, 医学部附属病院, 病院助教 (50467320)
Project Period (FY) 2008 – 2010
Project Status Completed (Fiscal Year 2010)
Budget Amount *help
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
KeywordsNek2 / TLK1 / FAK
Research Abstract

The cancer progression is dependent on complicated conditions of cancer specific genes. It is important to target the plural genes for the development of an effective molecule targeted therapy. We performed analysis about cancer specific genes, such as Nek2 (NIMA related kinase 2), FAK (Focal adhesion kinase) and TLK1 (Tousled like kinase 1). The simultaneous suppression of Nek2 and FAK inhibited proliferation and induced apoptosis, compared with single suppression of Nek2 or FAK. The double restraint of Nek2 and TLK1 also inhibited the proliferation and induced apoptosis. The combination treatment of Nek2 siRNA and CDDP increased inhibitory effect in proliferation and cell survival in cancer cell. We identified the over expression of BCL2L1 and APAF-1 (apoptotic protease activating factor 1), the suppression of FOS and JUN in combination treatment. The concomitant usage of TLK1 siRNA and CDDP enhanced apoptosis in comparison with TLK1 siRNA or CDDP treatment.
Our data indicated the combination of siRNA and the anticancer agent may be a novel cancer targeted therapy.

Report

(4 results)
  • 2010 Annual Research Report   Final Research Report ( PDF )
  • 2009 Annual Research Report
  • 2008 Annual Research Report
  • Research Products

    (12 results)

All 2010 2009 Other

All Journal Article (7 results) (of which Peer Reviewed: 6 results) Presentation (4 results) Remarks (1 results)

  • [Journal Article] Silencing of Tousled-like kinase 1 sensitizes cholangiocarcinoma cells to cisplatin-induced apoptosis.2010

    • Author(s)
      Takayama Y, Kokuryo T, Senga T.
    • Journal Title

      Cancer Lett. 296(1)

      Pages: 27-34

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Journal Article] Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin.2010

    • Author(s)
      Suzuki K, Kokurvo T, Hamaguchi M.
    • Journal Title

      Cancer Sci. 101(5)

      Pages: 1163-1169

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Journal Article] Inchinkoto, an herbal medicine, exerts beneficial effects in the rat liver under stress with hepatic ischemia-reperfusion and subsequent hepatectomy.2010

    • Author(s)
      Kawai K, Kokuryo T, Nagino M.
    • Journal Title

      Ann Surg. 251(4), 249(2)

    • Related Report
      2010 Final Research Report
  • [Journal Article] Silencing of Tousled-like kinase 1 sensitizes cholangiocazcinoma cells to cisplatin-induced apoptosis.2010

    • Author(s)
      Takayama Y, Kokuryo T, Nagino M., 他6名
    • Journal Title

      Cancer Lett.

      Volume: 296(1) Pages: 27-34

    • Related Report
      2010 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin.2010

    • Author(s)
      Suzuki K, Kolcuryo T, Nagino M
    • Journal Title

      Cancer Sci.

      Volume: 101(5) Pages: 1163-9

    • NAID

      10026592095

    • Related Report
      2010 Annual Research Report
    • Peer Reviewed
  • [Journal Article] A Novel Combination Treatment for Colorectal Cancer using Nek2 siRNA and Cisplatin2010

    • Author(s)
      Kazushi Suzuki, Toshio Kokuryo, Takeshi Senga, Yukihiro Yokoyama, Masato Nagino, Michinari Hamaguchi
    • Journal Title

      Cancer Science (In press)

    • NAID

      10026592095

    • Related Report
      2009 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Nek2 as a novel molecular target for the treatment of breast carcinoma.2009

    • Author(s)
      Tsunoda N, Kokuryo T, Nagino M.
    • Journal Title

      Cancer Sci. 100(1)

      Pages: 111-116

    • NAID

      10025141544

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Presentation] Nek2 as an effective molecular target for cancer treatment2010

    • Author(s)
      Kokuryo T, Senga T, Yokoyama Y, Nagino M, Hamaguchi M
    • Organizer
      AACR 101^<st> annual meeting
    • Place of Presentation
      Washington DC, USA
    • Year and Date
      2010-04-19
    • Related Report
      2010 Annual Research Report
  • [Presentation] Nek2 as an effective molecular target for cancer treatment2010

    • Author(s)
      Kokuryo T, Senga T, Yokoyama Y, Nagino M, Hamaguchi M.
    • Organizer
      AACR 101^<st>annual meeting
    • Place of Presentation
      Washington DC, USA
    • Related Report
      2010 Final Research Report
  • [Presentation] siRNAを用いた癌分子標的治療のトランスレーショナルリサーチ2010

    • Author(s)
      國料俊男、横山幸浩、梛野正人
    • Organizer
      JDDW 2010
    • Place of Presentation
      横浜
    • Related Report
      2010 Annual Research Report 2010 Final Research Report
  • [Presentation] 肝内結石症の網羅的遺伝子解析より始まった癌分子標的治療の開発2009

    • Author(s)
      國料俊男、横山幸浩、菅原元、江畑智希、西尾秀樹、梛野正人
    • Organizer
      日本肝胆膵外科学会
    • Place of Presentation
      名古屋
    • Year and Date
      2009-06-10
    • Related Report
      2009 Annual Research Report
  • [Remarks] ホームページ等

    • Related Report
      2010 Final Research Report

URL: 

Published: 2008-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi